Unknown

Dataset Information

0

Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial.


ABSTRACT:

Background

Co-crystal of tramadol-celecoxib (CTC), containing equimolar quantities of the active pharmaceutical ingredients (APIs) tramadol and celecoxib (100 mg CTC = 44 mg rac-tramadol hydrochloride and 56 mg celecoxib), is a novel API-API co-crystal for the treatment of pain. We aimed to establish the effective dose of CTC for treating acute pain following oral surgery.

Methods

A dose-finding, double-blind, randomised, placebo- and active-controlled, multicentre (nine Spanish hospitals), phase II study (EudraCT number: 2011-002778-21) was performed in male and female patients aged ≥ 18 years experiencing moderate to severe pain following extraction of two or more impacted third molars requiring bone removal. Eligible patients were randomised via a computer-generated list to receive one of six single-dose treatments (CTC 50, 100, 150, 200 mg; tramadol 100 mg; and placebo). The primary efficacy endpoint was the sum of pain intensity difference (SPID) over 8 h assessed in the per-protocol population.

Results

Between 10 February 2012 and 13 February 2013, 334 patients were randomised and received study treatment: 50 mg (n = 55), 100 mg (n = 53), 150 mg (n = 57), or 200 mg (n = 57) of CTC, 100 mg tramadol (n = 58), or placebo (n = 54). CTC 100, 150, and 200 mg showed significantly higher efficacy compared with placebo and/or tramadol in all measures: SPID (0-8 h) (mean [standard deviation]): - 90 (234), - 139 (227), - 173 (224), 71 (213), and 22 (228), respectively. The proportion of patients experiencing treatment-emergent adverse events was lower in the 50 (12.7% [n = 7]), 100 (11.3% [n = 6]), and 150 (15.8% [n = 9]) mg CTC groups, and similar in the 200 mg (29.8% [n = 17]) CTC group, compared with the tramadol group (29.3% [n = 17]), with nausea, dizziness, and vomiting the most frequent events.

Conclusion

Significant improvement in the benefit-risk ratio was observed for CTC (doses ≥ 100 mg) over tramadol and placebo in the treatment of acute pain following oral surgery.

Funding

Laboratorios del Dr. Esteve, S.A.U.

SUBMITTER: Lopez-Cedrun J 

PROVIDER: S-EPMC5995791 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial.

López-Cedrún José J   Videla Sebastián S   Burgueño Miguel M   Juárez Inma I   Aboul-Hosn Samir S   Martín-Granizo Rafael R   Grau Joan J   Puche Miguel M   Gil-Diez José-Luis JL   Hueto José-Antonio JA   Vaqué Anna A   Sust Mariano M   Plata-Salamán Carlos C   Monner Antoni A  

Drugs in R&D 20180601 2


<h4>Background</h4>Co-crystal of tramadol-celecoxib (CTC), containing equimolar quantities of the active pharmaceutical ingredients (APIs) tramadol and celecoxib (100 mg CTC = 44 mg rac-tramadol hydrochloride and 56 mg celecoxib), is a novel API-API co-crystal for the treatment of pain. We aimed to establish the effective dose of CTC for treating acute pain following oral surgery.<h4>Methods</h4>A dose-finding, double-blind, randomised, placebo- and active-controlled, multicentre (nine Spanish h  ...[more]

Similar Datasets

| S-EPMC10879371 | biostudies-literature
| S-EPMC10084286 | biostudies-literature
| S-EPMC7648778 | biostudies-literature
| S-EPMC10539230 | biostudies-literature
| S-EPMC6153956 | biostudies-literature
| S-EPMC9826359 | biostudies-literature
| S-EPMC5947135 | biostudies-other
| S-EPMC4986921 | biostudies-literature
| S-EPMC6394644 | biostudies-literature
| S-EPMC6256787 | biostudies-literature